NHS England commissioning update

Slides:



Advertisements
Similar presentations
Commissioning view of immunoglobulin Malcolm Qualie Head of Health Policy East Midland Specialised Commissioning Group.
Advertisements

Informatics priorities and strategy Chris Carrigan Deputy to the PHE Chief Knowledge Officer, Information Services.
Linda Ward Clinical Review & Effectiveness Specialist, EMSCG Primary care treatment funding decisions: developing a resource to.
Creating Better Health and Care Services An overview of a Better Health and Care Review process.
Diabetes Programme Progress Report Dr Charles Gostling, Joint Diabetes Clinical Director October 2013.
West London Mental Health NHS Trust CQC Action Plan Response to Recommendations Nigel McCorkell - Chairman Peter Cubbon – Chief Executive Ian Kent – Deputy.
London and South East Burns Services Review Patient Stakeholder Event 15 th January 2011 The Olympic Lodge Hotel, Aylesbury.
Developing a Referral Management Plan. Background Hospital referral rates in England have increased significantly over recent years, resulting in the.
Access to data for local authority public health AGW Public Health Network Training Event: Public Health Data, Information and Intelligence 11 th November.
Five Year Forward View: Personal Health Budgets and Integrated Personal Commissioning Jess Harris January 2016.
Care Quality Commission (CQC) Registration. Background The Care Quality Commission (CQC) is the health and social care regulator for England. From 1 April.
Training for organisations participating in Peer Review of Paediatric Diabetes.
Feedback from Stakeholder Engagement Event 6 th July 2016 Neonatal Service Review.
Our five year plan to improve local health and care services.
The Quality Surveillance Team / Programme
Adherence to Evidence Based Medicine Programme Evidence Summary Pack (Version 2) Hearing Aids Local commissioners working with local people for a healthier.
Sustainability and Transformation Partnership
Sustainability and Transformation Partnership
Knowledge for Healthcare: Driver Diagrams October 2016
Definition and Use of Clinical Pathways and Case Definition Templates
Our five year plan to improve local health and care services
Database and Data Update
Antibiotics: handle with care!
Uterovaginal Prolapse
Clinically Effective Commissioning (CEC)
Indicators and Outcomes Framework – relevance to patients and commissioners Parul Desai NHS England, London : 7 June 2016.
NHSE Commissioning update
National Immunoglobulin Database Meeting Procurement Update
Areas Separate Approaches Parallel Approaches Joint Approaches
Uterovaginal Prolapse
Adherence to Evidence Based Medicine Programme Evidence Summary Pack (Version 2) Hernia Local commissioners working with local people for a healthier.
Elaine Wyllie Executive Director of Joint Commissioning
Definition and Use of Clinical Pathways and Case Definition Templates
Adherence to Evidence Based Medicine Programme Evidence Summary Pack (Version 2) Knee Replacement Local commissioners working with local people for a.
Worcestershire Joint Services Review
UK IT Industry Awards – UK Public Sector Project of the Year
Personal Wheelchair Budget Programme
Integrating Clinical Pharmacy into a wider health economy
Improvement of management and reduction in mortality following implementation of audit recommendations in Clostridium difficile diarrhoea at James Cook.
An introduction to ACSA
Towards a Smokefree Generation: A Tobacco Control Plan for England South West Clinical Senate 21 September 2017
Annual General Meeting
Overarching Transformation narrative – progress so far and next steps
Have your say!.
Patient Engagement Group –Part 2 – Digital Transformation
Enfield Patient Participation Groups
Preventing VTE in hospitalised patients
Colin Parsons – Lead Nurse Specialist Adult Autism Service July 2017
Presentation Title 36pt Arial Bold
Neurological Services Deep Dive Workshop Understanding “what to change” using the NHS Right Care methodology Part of the NEW Devon Way.
Audit criterion Evidence
Dr Peter Groves MD FRCP Consultant Cardiologist
Somerset, Wiltshire, Avon & Gloucestershire Cancer Alliance
Commissioner Feedback for SLAM CQC Inspection in September 2015
OFFICIAL - SENSITIVE COMMERCIAL
Dry Eyes – Lubricant Eye Drops
Immunoglobulin Database Update
Immunoglobulin Database Data update 2017/18
The MSK-HQ Developing a generic Musculoskeletal Patient Reported Outcome Measure Policy & Public Affairs Team, Arthritis Research UK e.
Harrow CCG CCG 360o stakeholder survey 2014 Summary report.
Central and North West London NHS Foundation Trust
Worcestershire Joint Services Review
CCG Merger Proposal Consultation Event St Peter’s in the City, Derby
Adherence to Evidence Based Medicine Programme Evidence Summary Pack (Version 2) Correction of Ptosis Local commissioners working with local people for.
Consultation and Engagement
Independent Practitioner Chartered Society of Physiotherapy Council
Daniel Clarke (Advanced Specialist Pharmacist)
Stakeholder Engagement
NICE resources for STPs: MECC
Implementing the toolkit Training resources
Presentation transcript:

NHS England commissioning update Mandy Matthews 14th December 2018

Use of immunoglobulin in England NHS England is responsible commissioner for immunoglobulin 2017/18 annual spend approaching £190 million in England Commissioned in line with national Clinical Guidelines Significant supply issues in 2018 Patient care Resources required to manage supplies

Significant risks: Availability – nationally & globally On-going growth in use CART-T Market share of products and risk if a supply issue; product choice Variation in use, e.g. indication, dose, frequency Decision making – how robust, variation in IAPs, IFRs Data Impact of exit from EU?

Steps to manage risk: Improved collaborative working – Commercial medicines unit, clinicians, NHS England, Public Health England, MDSAS Immunoglobulin project working group Review of the current Clinical Guidelines for Immunoglobulin use Sub-regional Immunoglobulin Panels Proposed CQUIN for 2019/20 Proposed prior approval

Guidelines review: Launching 1st four sections: Haematology Immunology Infectious diseases (specific) Neurology Next steps: Review use in “other” indications, including other infection-related use Review evidence for grey indications Stakeholder consultation; updated based on feedback – launching via hubs Support IAPs to review existing patients Includes reference to alternative therapies – e.g. rituximab in MG; link to policies on last slide Advice on dosing in neurology Guidance available on IG in ID in line with PHE recommendations – only relates to hep A, measles, polio, tetanus, varicella. Use of Ig in other infection associated conditions, e.g. staph toxic shock syndrome, c. diff – will be considered in the next phase of the review

Sub-regional Immunoglobulin Assessment Panels (SRIAPs): Improve scrutiny & stewardship of immunoglobulin use Support demand management Manage usage within allocated volumes Improve communication channels in times of supply issues Compliance with NHS England commissioning guidance; review of existing patients; new patients Support data collection Looking at up to 20 IAPs in place across England – based on hub and spoke model. 6 in the North and in the South; 4 in London; 3 in M&E. Resources being provided include TOR, peer support via panel chairs’ calls, data

Immunoglobulin CQUIN: Provide funding to support the development of SRIAPs Role of SRIAPs in stewardship of immunoglobulin Ensure compliance with commissioning guidance Support implementation of prior approval A tool to support panels to deliver those actions detailed on previous slide

Prior approval: Automated system to approve use of Ig in line with updated guidance Approval required prior to use Options: MDSAS national immunoglobulin database Blueteq How to incorporate this into trust processes

Key messages: Importance of SRIAPs in managing demand New patients to meet eligibility criteria Review of existing patents in line with updated guidance Alternative therapies Data is key – usage & outcomes must be reported on the database

Prior Approval In your groups consider the following: Options: MDSAS national immunoglobulin database Blueteq Pros and cons of each system? Issues for providers? What would support implementation? Use to introduce group discussions on merits of prior approval, issues which will need to be overcome and pros/cons of each method. Record feedback on sheet on the table – 15 mins; then feedback to whole

Sub-regional Immunoglobulin Panels In your groups consider: Progress so far Issues, concerns Resources required to support the panel

Useful links: Rituximab, as a treatment option, in : Anti-NMDAR autoimmune encephalitis Cytopaenia complicating primary immunodeficiency Dermatomyositis and polymyositis Immunobullous Disease Commissioning policies and position statements are available at: https://www.england.nhs.uk/specialised-commissioning-document-library/routinely-commissioned-policies/ and https://www.england.nhs.uk/specialised-commissioning-document-library/policy-statements-urgent-policy-statements/ Public Health England provides advice on use of immunoglobulin at: https://www.gov.uk/government/publications/immunoglobulin-when-to-use